NCT06134102

Brief Summary

The study is observational, longitudinal, retrospective and prospective, on patients with PV. Patients with PV diagnosed from 2000 to 2023 according to WHO2017 criteria will be considered. The main purpose of the study is to determine the impact of clinical and laboratory characteristics of Polycythemia Vera on patients' prognosis, understood as long-term survival

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,150

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2019

Longer than P75 for all trials

Geographic Reach
1 country

22 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2019

Completed
4.8 years until next milestone

First Submitted

Initial submission to the registry

October 5, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

November 18, 2023

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

July 18, 2024

Status Verified

February 1, 2023

Enrollment Period

5 years

First QC Date

October 5, 2023

Last Update Submit

July 17, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Long-term survival

    To determine the impact of clinical and laboratory characteristics of Polycythemia Vera (PV) on patients' prognosis, in terms of lon term survival

    6 years

Secondary Outcomes (7)

  • Thrombosis

    6 years

  • Haemorrhages

    6 years

  • Therapies

    6 years

  • Therapies Toxicity

    6 years

  • Therapies Efficacy

    6 years

  • +2 more secondary outcomes

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The incidence of PV is approximately 11 x 1,000,000 patient-years. For the purpose of the registry, clinical/laboratory data collection will be expanded to 22 Hematology Centers experienced in the study of chronic myeloproliferative neoplasms. Overall, about 150 new diagnoses per year are expected from all Centers. Considering that about 20 percent of patients will not be able to be included for various reasons (lack of diagnosis according to WHO2017 criteria, patient's failure to refer to Hematology Centers, refusal to participate in the study), the registry is expected to include clinical data from about 2000 cases diagnosed from 2000 to the year 2023.

You may qualify if:

  • Patients diagnosed with PV according to WHO 2017 criteria,
  • Obtaining informed consent for data collection and processing

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (22)

Ospedale Casa Sollievo della Sofferenza

San Giovanni Rotondo, Apulia, 71013, Italy

Location

Grande Ospedale Metropolitano "Bianchi Melacrino Morelli"

Reggio Calabria, Calabria, 89124, Italy

Location

IRCCS Policlinico Sant'Orsola

Bologna, Emilia-Romagna, 40138, Italy

Location

Università degli studi di Ferrara - Nuovo Polo Ospedaliero di Cona - A.O.U. Arcispedale S. Anna

Ferrara, Emilia-Romagna, 44124, Italy

Location

Policlinico di Modena

Modena, Emilia-Romagna, 41125, Italy

Location

Azienda Ospedaliero-Universitaria di Parma

Parma, Emilia-Romagna, 43126, Italy

Location

AUSL di Piacenza - Palazzine Medicine Specialistiche

Piacenza, Emilia-Romagna, 29121, Italy

Location

Dipartimento Oncoematologico - AUSL della Romagna

Ravenna, Emilia-Romagna, 48121, Italy

Location

Arcispedale Santa Maria Nuova - IRCCS

Reggio Emilia, Emilia-Romagna, 42123, Italy

Location

Ospedale Infermi Rimini

Rimini, Emilia-Romagna, 47923, Italy

Location

A.O.U. Integrata di Udine

Udine, Friuli Venezia Giulia, 33100, Italy

Location

A.O.U. Policlinico Umberto I - Università degli Studi di Roma "La Sapienza"

Rome, Lazio, 00161, Italy

Location

IRCCS Azienda Ospedaliera Universitaria "San Martino" - IST

Genoa, Liguria, 16132, Italy

Location

IRCCS per l'oncologia -Ospedale Policlinico "San Martino"

Genoa, Liguria, 16132, Italy

Location

ASST Spedali Civili di Brescia

Brescia, Lombardy, 25123, Italy

Location

Ospedale San Gerardo

Monza, Lombardy, 20900, Italy

Location

A.O.U. Città della Salute e della Scienza - Presidio Molinette

Turin, Piedmont, 10126, Italy

Location

Ospedale "A. Businco" - Dipartimento Scienze Mediche e Sanità Pubblica Università degli Studi di Cagliari

Cagliari, Sardinia, 09131, Italy

Location

A.O.U. "Policlinico-V. Emanuele"- P.O. Ferrarotto

Catania, Sicily, 95124, Italy

Location

A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore

Pesaro, The Marches, 61122, Italy

Location

AOU di Padova

Padua, Veneto, 35128, Italy

Location

A.O.U. Integrata Verona - Borgo Roma

Verona, Veneto, 37134, Italy

Location

MeSH Terms

Conditions

Polycythemia Vera

Condition Hierarchy (Ancestors)

Bone Marrow NeoplasmsHematologic NeoplasmsNeoplasms by SiteNeoplasmsBone Marrow DiseasesHematologic DiseasesHemic and Lymphatic DiseasesMyeloproliferative Disorders

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 5, 2023

First Posted

November 18, 2023

Study Start

January 1, 2019

Primary Completion

December 31, 2023

Study Completion

December 31, 2023

Last Updated

July 18, 2024

Record last verified: 2023-02

Locations